💊AHRQ Request for Evidence on Managing Menopausal Symptoms
The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review on Improving the Management of Menopausal Symptoms in Perimenopausal and Early Postmenopausal Women: A Systematic Review, which is currently being conducted by the AHRQ's Evidence-based Practice Centers (EPC) Program. Access to published and unpublished pertinent scientific information will improve the quality of this review.
Learn More🦷Notice of Closed Meeting on Dental & Craniofacial Research Grants
The National Institutes of Health announces a closed meeting of the Special Emphasis Panel to evaluate grant applications for innovative research in dental, oral, and craniofacial areas. The meeting will be virtual and focuses on reviewing proposals, potentially influencing future funding in the dental health sector.
Learn More🏥National Institute on Aging Closed Meeting Notice for Grant Applications
The Department of Health and Human Services announces a closed meeting of the National Institute on Aging to evaluate grant applications. This meeting aims to discuss confidential matters related to aging research. The committee will assess various proposals, impacting stakeholders in the field by determining the allocation of funding for research initiatives related to aging.
Learn More💰Notice of Closed Meeting for NIAID Grant Opportunities
This document announces a closed meeting of the National Institute of Allergy and Infectious Diseases Special Emphasis Panel to review grant applications. The meeting focuses on potential financial evaluations of scientific proposals and outlines procedural information for participating stakeholders.
Learn More🗣️Briefing on Language Access for Individuals with Limited English Proficiency
The U.S. Commission on Civil Rights is holding a public briefing to address the challenges posed by language barriers in accessing government services and healthcare for individuals with limited English proficiency. Experts will discuss the current landscape of language access, including best practices and lived experiences of affected individuals. The meeting encourages public participation and comments for report preparation.
Learn More🩺DOL Seeks Comments on COVID-19 Recordkeeping Information Collection
The Department of Labor (DOL) is submitting this Occupational Safety & Health Administration (OSHA)-sponsored information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). Public comments on the ICR are invited.
Learn More🧠NIH Announces Closed Meetings for Grant Application Reviews
The Department of Health and Human Services announces closed meetings for the National Institute of Neurological Disorders and Stroke to review grant and cooperative agreement applications. The discussions involve confidential information, emphasizing the significance of funding in advancing neurological research and collaborations.
Learn More🎓Upcoming NIH Grant Review Meetings for Cancer Research in 2025
This notice announces several closed meetings by the National Cancer Institute where grant applications will be reviewed for the SBIR/STTR program. The meetings, to be held virtually in April and May 2025, will evaluate significant proposals aimed at advancing cancer research and treatment initiatives.
Learn More🧬NIH Notice
The Department of Health and Human Services announces a closed meeting of the National Human Genome Research Institute to review grant applications. Attending members will evaluate submissions that may include confidential information, impacting future funding opportunities in the field of genome research and biotechnology.
Learn More💊FDA Withdraws Approval for ZULRESSO (Brexanolone) Solution
The Food and Drug Administration (FDA or Agency) is withdrawing approval of a new drug application (NDA) for ZULRESSO (brexanolone) solution, 100 milligrams (mg)/20 milliliters (mL), held by Sage Therapeutics, Inc., 55 Cambridge Parkway, Cambridge, MA 02142 (Sage). Sage notified the Agency in writing that the drug product was no longer marketed and requested that the approval of the application be withdrawn.
Learn More